To test whether TIA1 can directly modulate CD8+-cell function, we co-cultured CFSE-labeled human CD8+ T cells with T24 bladder cancer cells engineered for TIA1 gain- or loss-of-function. This evidence concerns the gene CD8A and urinary bladder carcinoma.